FDA Grants Seven-Year Orphan-Drug Exclusivity for Onapgo
SUPN is trading near its 52-week low of $37.54 (9.9% above the low).
Summary
The FDA granted Onapgo seven years of orphan-drug exclusivity, locking out generic competition for the product in its rare-disease indication through roughly 2033. That is a durable revenue moat for a company that just posted $219.1 million in quarterly revenue and raised full-year guidance. The timing matters: shareholders vote October 15 on the all-stock merger with Indivior, and a protected Onapgo asset strengthens the combined CNS franchise's pipeline story. No dollar terms were disclosed, so the near-term financial impact is not quantified.
At the time of this announcement, SUPN was trading at $41.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $37.54 to $59.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.